Last reviewed · How we verify

Amlodipine (Norvasc) — Competitive Intelligence Brief

Amlodipine (Norvasc) (Amlodipine (Norvasc)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Cardiovascular.

marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine (Norvasc) (Amlodipine (Norvasc)) — Bayer. Amlodipine blocks calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amlodipine (Norvasc) TARGET Amlodipine (Norvasc) Bayer marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Losartan and Amlodipine Losartan and Amlodipine Centro Universitario de Ciencias de la Salud, Mexico marketed Angiotensin II receptor antagonist + Calcium channel blocker combination AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)
Amlodipine+intensive antihypertensive therapy Amlodipine+intensive antihypertensive therapy Beijing Tiantan Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
amlodipine/hydrochlorothiazide amlodipine/hydrochlorothiazide Shanghai Jiao Tong University School of Medicine marketed Calcium channel blocker / Thiazide diuretic combination L-type voltage-gated calcium channel (amlodipine); Sodium-chloride cotransporter (hydrochlorothiazide)
Amlodipine placebos Amlodipine placebos Shenzhen Ausa Pharmed Co.,Ltd marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Standard medication for variant angina Standard medication for variant angina Seoul National University Hospital marketed Calcium channel blocker L-type voltage-gated calcium channel
Amlodipine plus Metformin Amlodipine plus Metformin Third Military Medical University marketed Combination therapy: calcium channel blocker + biguanide antidiabetic L-type voltage-gated calcium channels (amlodipine); AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

  1. Bayer · 2 drugs in this class
  2. Beijing Tiantan Hospital · 2 drugs in this class
  3. GlaxoSmithKline · 1 drug in this class
  4. Guangzhou First People's Hospital · 1 drug in this class
  5. Organon and Co · 1 drug in this class
  6. Peking University First Hospital · 1 drug in this class
  7. Pfizer Inc. · 1 drug in this class
  8. SK Chemicals Co., Ltd. · 1 drug in this class
  9. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
  10. Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine (Norvasc) — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-norvasc. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: